Key ASIC Berhad (KLSE:KEYASIC)

Ligand Pharmaceuticals Cash Flow Statement

Financials in millions MYR. Fiscal year is June - May.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	May 31, 2025	May 31, 2024	May 31, 2023	May 31, 2022	May 31, 2021
Net Income	-6.41	-10.77	-5.37	-8.64	-7.96
Depreciation & Amortization	1.85	2.26	2.09	2.13	2.03
Other Amortization	-	0	-	0.02	0.02
Asset Writedown & Restructuring Costs	3	-	-	2.88	-
Stock-Based Compensation	0.37	1.89	2.71	-	3.01
Provision & Write-off of Bad Debts	-	0.02	-0.66	0	-1.93
Other Operating Activities	-0.08	-0.06	0.13	-0.13	-0.05
Change in Accounts Receivable	-1.11	-0.43	-2.36	-0.73	2.69
Change in Inventory	-0.15	0.59	-0.21	0.33	-1.61
Change in Accounts Payable	-1.06	1.74	2.45	-0.54	-2.56
Operating Cash Flow	-3.6	-4.77	-1.21	-4.67	-6.35
Capital Expenditures	-0.03	-1.35	-0.09	-0.11	-0.98
Sale (Purchase) of Intangibles	-4.73	-0.09	-	-0.01	-
Other Investing Activities	-	-0.07	-0	-0.03	-
Investing Cash Flow	-4.76	-1.51	-0.09	-0.15	-0.98
Short-Term Debt Issued	0.01	0.08	0.1	0.04	0.1
Total Debt Issued	0.01	0.08	0.1	0.04	0.1
Short-Term Debt Repaid	-	-	-	-0	-
Long-Term Debt Repaid	-0.57	-0.5	-0.48	-0.52	-0.47
Total Debt Repaid	-0.57	-0.5	-0.48	-0.52	-0.47
Net Debt Issued (Repaid)	-0.55	-0.41	-0.39	-0.48	-0.37
Issuance of Common Stock	-	0.12	0.81	6.92	21.09
Financing Cash Flow	-0.55	-0.29	0.42	6.44	20.72
Foreign Exchange Rate Adjustments	-0.27	0.22	0.38	0.4	0.08
Net Cash Flow	-9.18	-6.35	-0.49	2.02	13.47
Free Cash Flow	-3.63	-6.12	-1.29	-4.78	-7.32
Free Cash Flow Margin	-25.14%	-26.70%	-6.22%	-35.21%	-52.77%
Free Cash Flow Per Share	-0.00	-0.01	-0.00	-0.00	-0.01
Cash Interest Paid	-	0.03	0.04	0.01	0.02
Cash Income Tax Paid	-	0.01	0	-	0.02
Levered Free Cash Flow	-6.53	-2.52	0.73	-4.54	-4.46
Unlevered Free Cash Flow	-6.53	-2.5	0.76	-4.54	-4.45
Change in Net Working Capital	-0.5	-1.96	0.31	0.72	3.43

Source: S&P Global Market Intelligence. Standard template. Financial Sources.